ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 144 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,768,284 | -73.3% | 333,010 | -52.0% | 0.00% | -100.0% |
Q2 2023 | $6,616,880 | +143.6% | 694,321 | +181.1% | 0.00% | 0.0% |
Q1 2023 | $2,716,736 | -34.4% | 246,976 | -11.7% | 0.00% | 0.0% |
Q4 2022 | $4,139,042 | +18.2% | 279,665 | +52.6% | 0.00% | 0.0% |
Q3 2022 | $3,503,000 | +70.9% | 183,297 | +90.6% | 0.00% | – |
Q2 2022 | $2,050,000 | +70.1% | 96,178 | +53.7% | 0.00% | – |
Q1 2022 | $1,205,000 | +20.5% | 62,573 | +29.7% | 0.00% | – |
Q4 2021 | $1,000,000 | +3.0% | 48,234 | +18.7% | 0.00% | – |
Q3 2021 | $971,000 | +12.1% | 40,627 | +27.9% | 0.00% | – |
Q2 2021 | $866,000 | +39.9% | 31,759 | +48.4% | 0.00% | – |
Q1 2021 | $619,000 | -90.2% | 21,397 | -90.5% | 0.00% | -100.0% |
Q4 2020 | $6,322,000 | +20.3% | 224,765 | +25.3% | 0.00% | +100.0% |
Q3 2020 | $5,256,000 | +1.1% | 179,376 | +4.3% | 0.00% | -50.0% |
Q2 2020 | $5,199,000 | -12.6% | 171,914 | -13.9% | 0.00% | 0.0% |
Q1 2020 | $5,949,000 | – | 199,630 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |